MedTrace Logo

Metastatic Thyroid Cancer Therapy Optimization With 124I PET Dosimetry

NCT05299437 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2022-03-29

No results posted yet for this study

Summary

Failure of conventional radioiodine therapy of metastatic differentiated thyroid cancer could be explained by:

* a suboptimal therapeutic approach, based on the administration of empirically fixed amount of radioactivity
* the presence of lesions with impaired iodine uptake, due to the expression of specific mutations

The study aims to:

* optimize therapy with pre-treatment 124-I blood and lesion dosimetry
* collect genetic data to check if specific mutations and/or miRNA over-expression could be related to low iodine uptake or to radioresistance

Conditions

  • Metastatic Differentiated Thyroid Cancer

Interventions

DRUG

Radioiodine optimized therapy

124-I blood and lesion dosimetry will be used to optimize the 131-I therapeutic activity. Both 124-I and 131-I administration will be performed after hormon withdrawal. Primary tumour tissue and circulating miRNA will be analyzed to check the genetic status.

Sponsors & Collaborators

  • Associazione Italiana per la Ricerca sul Cancro

    collaborator OTHER

  • Carlo Chiesa

    lead OTHER

Principal Investigators

  • Carlo Chiesa, PhD · Nuclear Medicine, Fondazione IRCCS Istituto Nazionale Tumori

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-05-12
Primary Completion
2024-03-30
Completion
2024-09-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05299437 on ClinicalTrials.gov